title: Primary stenting is nowadays the gold standard treatment for TASC II A & B iliac lesions: the definitive MISAGO 1-year results.
abstract: BACKGROUND
  The MISAGO ILIAC Study is a prospective, non-randomized, multicenter, bi-national, monitored trial, conducted in 3 hospitals in Belgium and 2 hospitals in Germany. This manuscript reports the findings up to 12-month follow-up time for the total cohort. The primary endpoint of the study was primary patency, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, peak systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR), within 12 months.
  
  
  METHODS
  Between September 2011 and April 2012, 120 patients with TASC II Class A or TASC II Class B aortoiliac lesions were included. The cumulative lesion length in the overall population was 45.49 mm with a maximum stenosis pre-treatment of 83.76%. The demographic data were compatible for the TASC II class A and TASC II class B cohort. One patient with a TASC II class C was included as a protocol deviation.
  
  
  RESULTS
  The primary patency rate for the total patient population was 97.4%. The primary patency rates at 12 months for the TASC II class A and TASC II class B(C) lesions were respectively 98.3% and 96.6%. No statistical significant difference was shown when comparing these 2 groups (P=0.6407).
  
  
  CONCLUSIONS
  Our findings confirm that nowadays primary stenting with modern generation stents replaced the more invasive surgery as the golden standard treatment for patients with TASC II class A and B aortoiliac lesions.
authors.affiliation: Department of Vascular Surgery, AZ Sint‑Blasius, Dendermonde, Belgium - office@fmrp.be.
authors.forename: Koen
authors.initials: K
authors.lastname: Deloose
authors.affiliation: Department of Vascular Surgery, AZ Sint‑Blasius, Dendermonde, Belgium.
authors.forename: Marc
authors.initials: M
authors.lastname: Bosiers
authors.affiliation: Department of Vascular Surgery, AZ Sint‑Blasius, Dendermonde, Belgium.
authors.forename: Joren
authors.initials: J
authors.lastname: Callaert
authors.affiliation: Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Verbist
authors.affiliation: Department of Thoracic and Vascular Surgery, University Hospital Gent, Gent, Belgium.
authors.forename: Frank
authors.initials: F
authors.lastname: Vermassen
authors.affiliation: Department of Angiology, Leipzig Heart Center, Leipzig, Germany.
authors.forename: Dierk
authors.initials: D
authors.lastname: Scheinert
authors.affiliation: Department of Vascular Surgery, St. Franziskus Hospital and University Hospital of Münster, Münster, Germany.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Torsello
authors.affiliation: Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium.
authors.forename: Patrick
authors.initials: P
authors.lastname: Peeters
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001018:Aortic Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D001530:Belgium; D001783:Blood Flow Velocity; D003251:Constriction, Pathologic; D057510:Endovascular Procedures / Q000009:adverse effects / Q000295:instrumentation*; D005260:Female; D005858:Germany; D006801:Humans; D007083:Iliac Artery / Q000000981:diagnostic imaging / Q000503:physiopathology; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D011446:Prospective Studies; D011474:Prosthesis Design; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex; D014654:Vascular Patency